Tags : Shionogi

Shionogi to Acquire Tetra Therapeutics for ~$500M

Shots: Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones, based on certain achievements. Following the acquisition, Shionogi will get global rights to Tetra’s portfolio for CNS disorders including BPN14770 In 2018, the two companies collaborated and in 2020 expand their alliance to develop and commercialize […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: The US FDA New Drug Approvals in November 2019

The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year’s record of approvals. However, there is a significant […]Read More

PharmaShots Weekly Snapshot (November 11-15, 2019)

Roche’s Kadcyla (trastuzumab emtansine) Receives CHMP’s Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment Published: Nov 15, 2019 | Tags: Roche, Kadcyla, trastuzumab emtansine, Receives, CHMP, Recommendation, Approval, Adjuvant, Treatment, HER2+ Early Breast Cancer 2. Stanford Medicine Reports Results of Apple Heart Study for Detecting […]Read More

Shionogi’s Fetroja (cefiderocol) Receives the US FDA’s Approval for the

Shots: The US FDA approval is based on APEKS-cUTI study assessing Fetroja vs imipenem/cilastatin (IPM/CS) in patients aged ≥18yrs. with cUTI who have limited or no alternative treatment options The pivotal APEKS-cUTI study resulted in higher response rate in microbiological eradication and clinical response at the test of cure (TOC), met its 1EPs (72.6% vs […]Read More

BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to

Shots: Shionogi to receive $30M upfront ($20M as initial payment & additional $10M in 6mos.) and royalties based on the sales of Symproic. BDSI to get exclusive commercialization rights for Shionogi’s Symproic (naldemedine, 0.2mg) in the US and Puerto Rico The focus of the agreement is to strengthen the BDSI’s portfolio with expected company’s net […]Read More

Sandoz Signs a Commercialization Agreement with Shionogi for Rizmoic (naldemedine)

Shots: Sandoz to get commercialization rights for Rizmoic (naldemedine) in Germany, UK and the Netherlands with rights of first refusal for other European markets. Shionogi will be responsible for Rizmoic’s manufacturing & development The focus of the agreement is to enhance Sandoz’s anti-pain portfolio for minimizing the side-effects of opioid use in Europe Rizmoic (naldemedine,0.2mg) […]Read More

Shionogi Signs a Research Collaboration with UBE Industries for the

Shots: Shionogi and UBE Industries collaborates for development of anti-RS (respiratory syncytial) virus drugs to treat Respiratory Syncytial Virus (RSV) infection The focus of the agreement is to combine Shionogi’s drug discovery platform with UBE’s drug design technology for SAR (Structure-Activity Relationship) study UBE Industries’ Drug discovery platform uses polymer synthesis technology for the development […]Read More